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Abstract
 .The newly synthesized calcium channel blocker, Ro44-5912, significantly potentiates doxorubicin Dox -induced
cytotoxicity at non-cytotoxic concentrations in Dox-resistant human ovarian cell line, A2780rDX5, overexpressing
 .  .P170-glycoprotein Pgp . Induction of DNA single- and double-strand breaks ssbs and dsbs was measured using alkaline
 .elution and constant-field gel electrophoresis CFGE assays. The results indicate that potentiation of the cytotoxicity of
Dox by Ro44-5912 was accompanied by significant increases in both, Dox-induced DNA ssbs and dsbs in the resistant
 .cells. Pulsed-field gel electrophoresis PFGE analysis showed that Dox induced DNA fragments in the 50–800 kilobase
 .  .kb and 0.8–5.7 megabase Mb ranges. The majority of the newly synthesized DNA fragments were in the 50–800 kb
range. Ro44-5912 treatment resulted in significant potentiation of DNA fragmentation in the 50–800 kb range with a minor
increase in 0.8–5.7 Mb DNA fragments, suggesting that the modulator functions by potentiating nascent DNA fragmenta-
tion in the resistant cells. Exposure to Dox with Ro44-5912 was associated with a prolonged blockage of cells in the
 .S-phase. In contrast, exposure to Dox alone resulted in temporary blockage of cells in G rM phase ;24 h followed by2
restoration of cell proliferation and normal DNA histograms at 48 h after 2 h drug exposure. Incorporation of BrdUrd by
flow cytometric analysis was inhibited by Dox in the presence of Ro44-5912, showing that there is a block of DNA
replication. An increased damage in newly synthesized DNA could concur with a blocked DNA replication. Moreover,
slowing progression through the S-phase in cells exposed to Dox in combination with Ro44-5912 is accompanied by
increased sensitivity of Dox poisons, indicating a correlation of specific S-phase perturbation with the reversal of Dox
resistance by Ro44-5912 in cells expressing Pgp. The results suggest that drug-induced augmentation of nascent DNA
fragmentation and specific cell-cycle perturbation are potentially important molecular determinants for reversal of multidrug
resistance in addition to restoration of intracellular drug retention. q 1998 Elsevier Science B.V.
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1. Introduction
Resistance to a broad spectrum of current clini-
cally available agents is one of the major obstacles to
w xcurative cancer chemotherapy 1,2 . One of the most
intensely scrutinized mechanism of resistance is mul-
 .tidrug resistance MDR , defined as resistance to a
w xvariety of lipophilic compounds 3,4 with different
structures and mechanisms of action. MDR has been
associated with the overexpression of either 170 kDa
 .transmembrane glycoprotein Pgp or 190 kDa inte-
 . w xgral membrane phosphoglycoprotein MRP 5–8 .
Pgp and MRP function as an energy-dependent efflux
pump and serve to decrease accumulation of struc-
turally unrelated cytotoxic agents in the intracellular
w xmilieu 2,5 .
Significant progress has been achieved in elucidat-
ing the pump pathway mediating MDR. Several re-
ports have described calcium antagonists and cy-
 .closporin analogs e.g. PSC-833 as potentiators of
 .the cytotoxic effect of doxorubicin Dox by restoring
the intracellular drug accumulation and retention in
w xPgp-expressing MDR cells 9–13 . A new pyridine
analog, PAK-104P, is effective in the reversal of
in-vitro and in-vivo resistance to Dox in both Pgp
w xand MRP expressing tumors 14–17 . The reversal of
Dox resistance by PAK-104P was associated with a
restoration of intracellular drug accumulation and
retention. At equicytotoxic concentrations of Dox
with, or without the modulator, the intracellular drug
retention was significantly higher in drug-resistant
cells than in sensitive cells. Thus, although restora-
tion of intracellular drug concentration is an essential
step for reversal of MDR, it is not sufficient for
w xcomplete restoration of drug sensitivity 14 .
In addition to restoration of intracellular drug re-
tention, reversal of MDR by Ro44-5912, a newly
synthesized calcium channel blocker, might involve
the induction of other specific types of molecular
lesions. DNA damage can occur at the genomic and
w xnewly synthesized DNA sites 18 . Nascent DNA
fragmentation is generated predominantly at sites of
replication and not in the bulk DNA. Double-strand
 .breaks dsbs formed in replicating DNA are the
w xlethal drug-induced lesions 18–21 . The induction of
nascent DNA fragmentation requires ongoing DNA
replication and the replication of eukaryotic genome
w xis restricted to S-phase 22,23 . Thus, the induction of
dsbs in nascent DNA may be associated with specific
cell-cycle perturbation. In order to test this hypothe-
sis, we have assessed DNA damage in mature and
nascent DNA and analyzed cell-cycle distribution in
drug-sensitive and resistant cells exposed to Dox
alone or in combination with Ro44-5912. We further
attempted to investigate whether the above-men-
tioned molecular alterations are correlated to the re-
versal of multidrug resistance.
2. Materials and methods
2.1. Drugs and chemicals
Doxorubicin HCl, USP, for injection was manufac-
 .tured by Farmitalia Carlo Erba S.P.A. Milan, Italy .
 .Ro44-5912 Fig. 1 was kindly supplied by Nippon-
 .Roche K.K. Japan . Ro44-5912 was dissolved in
 .DMSO 0.02 M stock solution and then diluted using
growth medium. Proteinase K and RNase A were
obtained from Boehringer Mannheim Indianapolis,
. 14  . 3IN . C-dThyd sp. act. 56 mCirmmol and H-
 .dThyd sp. act. 20 Cirmmol were purchased from
 .Moravek Biochemical Brea, CA and DuPont NEN
 .Boston, MA , respectively.
2.2. Cell line and growth inhibition assay
Human ovarian cancer cell line A2780rwt was
w xestablished from cells of an untreated patient 24 .
A2780rDX5 cells were selected by the exposure of
Dox-sensitive cells to increasing concentrations of
w xDox 17 . Parental and Dox-resistant cell lines were
both cultured in RPMI 1640 medium supplemented
with 10% fetal bovine serum and 2 mM glutamine.
Fig. 1. Chemical structure of Ro44-5912.
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The detection of Mycoplasma in cultured cells was
performed using GEN-PROBE Mycoplasma T.C.
rapid detection system every two months GEN-
.PROBE, San Deigo, CA . For determination of in-
vitro cell growth inhibition, the total protein assay
w xwas used as described elsewhere 25,26 . In brief,
1000 cellsrwell were seeded in 96-well plates. After
24 h, exponentially growing cells were treated with
drug for 2 h and then incubated in drug-free medium
in the presence, or absence of Ro44-5912. Following
three doubling times after drug exposure, the cells
 .were fixed with 10% trichloroacetic acid TCA and
further processed according to the published SRB
procedure. The absorbance was measured at 570 nm
using an automated Bio Kinetics reader Model EL
.340, Bio-Tek Instruments, Wnooski, VT .
2.3. Rhodamine-123 and Dox retention
Cells were treated with 5mgrml of Rhodamine-
 .123 Rh 123 during the last 20 min of a 12 h modula-
 .tor pre-incubation. Rh 123 stock solution 1 mgrml
was freshly prepared with water and filtered. The
cells were washed twice with PBS and then incubated
for an additional 1 h in the presence, or absence of
the modulator. Rh 123 fluorescence was analyzed by
a FACScan flow cytometer Becton Dickinson, San
.Jose, CA in order to evaluate Rh 123 retention.
For Dox retention analysis, cells were initially
exposed to equicytotoxic concentrations of Dox for
 .2 h, washed 0-time and incubated in a drug-free
medium with, or without Ro44-5912 for 4 h. Dox
mean fluorescence channel number by flow cytome-
try was then determined as has been described re-
w xcently 14 .
2.4. Flow cytometric analysis of DNA content and
BrdUrd incorporation
Exponentially growing cells were exposed to drug
for 2 h, washed twice and maintained in a drug-free
medium with, or without the modulator. At various
time intervals, cells were harvested. Approximately
106 cells were resuspended in 1 ml of modified Kris-
han buffer with propidium iodide PI, Molecular
. Probes, Eugene, OR 0.1% sodium citrate,
0.02 mgrml RNase A, 0.37% NP40 and 0.05%
.mgrml PI, pH 7.4 and kept on ice protected from
light for 30–60 min. The cells were pelleted, resus-
pended in fresh modified Krishan buffer with PI and
filtered through a 30–50 mm filter. The samples were
analyzed for DNA content on a FACScan flow cy-
tometer.
For BrdUrd labeling, exponentially growing cells
were treated with 50 mM Dox or 10 mM Dox with
2 mM Ro44-5912 for 2 h. The cells were labeled with
 .10 mM BrdUrd Sigma, St. Louis, MO 20 min prior
to cell harvest at each time point. When fixed in
ethanol, cells were labeled with FITC-conjugated
anti-BrdUrd antibody Boehringer-Mannheim, Indi-
.  .anapolis, IN and PI 10 mgrml . Combined analysis
of DNA content vs. BrdUrd labeling was performed
using WinList software version 2.0; Verity Software
.House, Topsham, ME .
2.5. Alkaline elution
DNA ssbs were quantified by the alkaline elution
assay according to methods described by Kohn et al.
w x27,28 . Cells were pre-labeled with 0.025 mCirml of
14  . 3C-dThyd for test cells or 0.5 mCirml of H-dThyd
 . 14for reference cells for 20 h. The C-labeled cells
were treated with drug and the 3H-labeled cells were
exposed to 300 rad of X-irradiation. Approximately
5 14  .4=10 C-labeled cells for test cells mixed with
3 the same number of H-labeled cells for reference
.cells were lysed with 2% SDSr0.025 M Na EDTA,4
pH 9.7, in the presence of 0.25 mgrml of proteinase
K. Elution was carried out in the dark with
TPOHrEDTA containing 0.1% SDS, pH 12.1, at
2 mlrh.
2.6. Preparation of agarose plugs and gel elec-
trophoresis analysis
The procedure of preparation of DNA plugs is a
w xmodification of that of Schwartz et al. 29 and
w xGiaccia et al. 30 . For CFGE, agarose gels were
prepared in 1=TAE buffer 40 mM Tris-acetate,
.1 mM EDTA , pH 8.3. A conventional horizontal
submerged unit was used. Electrophoresis was per-
formed in TAE buffer at room temperature. DNA
was stained with ethidium bromide. For quantitative
analysis of DNA dsbs, the cells were pre-labeled with
14C-dThyd for 24 h. Following CFGE, each band was
( )M.-b. Yin et al.rBiochimica et Biophysica Acta 1401 1998 265–276268
cut out, and the quantity of 14C-labeled DNA frag-
ments was determined by scintillation counting.
For PFGE, agarose gels were prepared in 0.5=
BRL TBE buffer 75 mM Tris, 25 mM boric acid and
.0.1 mM EDTA, pH 8.9 . Electrophoresis was carried
out using Hex-A-Field horizontal gel electrophoresis
 .apparatus GIBCO-BRL , which contains a hexago-
nal array of electrodes having a reorientation angle of
1208. The electrophoresis was performed in TBE
buffer at 148C with buffer circulation. To resolve
0.05–1.9 and 1.9–5.7 Mb DNA fragments, PFGE
was carried out in two phases as previously described
w x18,31 : phase I – 20 min pulse time, 48 h running
time; and phase II – 6 min pulse time, 24 h running
time. Following PFGE, the gels were stained with
ethidium bromide to reveal the amount of DNA
fragments in each lane. To analyze drug-induced dsb
patterns in nascent DNA, cells were first exposed to
drug for 2 h, then labeled with 3H-dThyd during the
last 2 h of the 24 h drug-free incubation in medium
with, or without modulator prior to preparation of
DNA plugs. Following PFGE, the gels were dried out
and exposed to X-ray film at y708C using intensify-
 .ing screens DuPont .
3. Results
3.1. Re˝ersal of Dox resistance by Ro44-5912
The sensitivity of A2780rwt and A2780rDX5
cells to Dox and the potentiation effect of Ro44-5912
on Dox-induced cell growth inhibition were investi-
gated and the results illustrated in Fig. 2. The IC50
values of 2 h exposure to Dox were approximately
0.2 and 3.6 mM in the sensitive and resistant cell
lines, respectively. When Ro44-5912 was added at a
non-cytotoxic concentration of 2 mM, the IC for50
Dox, in the resistant cells, shifted from 3.6 to 0.5 mM
 .approximately 7.2-fold drug modification . In con-
trast, coincubation of Dox with 2 mM Ro44-5912 had
no detectable effects on Dox-induced cell growth
inhibition in A2780rwt cells. These results demon-
strate that Ro44-5912 can potentiate cell growth inhi-
Fig. 2. Modulation of in-vitro growth inhibition of Dox by Ro44-5912. Exponentially growing cells were treated with varying
concentrations of Dox in the presence, or absence of 2 mM Ro44-5912 for 2 h, washed twice with PBS and then incubated in drug-free
medium with, or without the modulator for an additional 72 h. Growth inhibition was determined by the total protein SRB assay as
described in Section 2. Results represent the mean of more than three experiments"SD.
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Fig. 3. Effects of Ro44-5912 on Rh 123 retention. 1=106 exponentially growing cells were exposed to 5mgrml of Rh 123 during the
last 20 min of 12 h pre-incubation with 2 mM Ro44-5912; washed twice and then incubated in fresh medium in the presence, or absence
of the modulator. Rh 123 retention was determined by flow cytometry. The x-axis represents the relative intensity of fluorescence and the
y-axis represents the absolute number of cells.
bition of Dox in vitro in drug-resistant A2780rDX5
cells expressing Pgp. However, reversal of Dox resis-
tance by Ro44-5912 was incomplete, since these cells
remained 2.5-fold resistant.
3.2. Rh 123 and Dox retention
The effects of Ro44-5912 on Rh 123 retention
were examined and the results shown in Fig. 3. At a
 .non-cytotoxic concentration of the modulator 2 mM ,
Rh 123 retention in A2780rDX5 cells was increased
to the same level as in A2780rwt cells. The modula-
tor, however, had no significant effect on the accu-
mulation nor on the retention of Rh 123 in drug-sen-
sitive cells. The data in Table 1 indicate that at
equicytotoxic concentrations of Dox, a higher level of
Dox accumulation was achieved immediately after
 .2 h exposure 0-time in A2780rDX5 cells with a
significant decrease at 4 h thereafter. In the presence
of the modulator, intracellular retention remained high
at 4 h. Despite the complete restoration of intra-
cellular drug retention by the modulator, the reversal
of resistance was only partial. Higher intracellular
drug retention in the resistant cells as compared to
the parental cell line was necessary to achieve an
equicytotoxic condition. The data obtained using the
 .Rh 123 uptake assay Fig. 3 were in agreement with
 .that obtained by the Dox uptake assay Table 1 .
3.3. Effects of Ro44-5912 on Dox-induced DNA ssbs
and dsbs
The extent of DNA ssbs and dsbs in A2780rwt
and A2780rDX5 cells exposed to Dox with, or
Table 1
Dox intracellular accumulation and retention by A2780rwt and
A2780rDX5 cells
Cell IC Mean fluorescence channel90
 . a amM 0-time 4 h
A2780rwt 1.85 20.4"3.7 22.1"2.9
A2780rDX5 50 47.5"0.7 12.5"3.5
 .no modulator
A2780rDX5 10 50.5"0.7 50.5"4.5
q2 mM Ro44-5912
a Time after 2 h exposure.
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Fig. 4. Alkaline elution analysis for Ro44-5912 effect on Dox-in-
duced DNA ssbs. Exponentially growing A2780rDX5 cells were
14 pre-labeled for 20 h with 0.025mCirml of C-dThyd for test
. 3  .cells or with 0.5mCirml of H-dThyd for reference cells .
14C-labeled cells were treated for 2 h with Dox alone, or in
combination with 2 mM Ro44-5912; washed twice and then
incubated in drug-free medium with, or without 2 mM Ro44-5912.
DNA ssbs were quantified at 0, 2, 4 and 8 h after initial 2 h drug
treatment by alkaline elution as described in Section 2.
without Ro44-5912 was quantified by alkaline elution
 .  .Fig. 4 and CFGE Fig. 5 . At equicytotoxic concen-
trations of Dox, we observed a high level of DNA
ssbs induced by Dox in the wild type and a rather
lower effect in the resistant cell line. As shown in
 .Fig. 4 C and D , DNA ssbs decrease with time in the
resistant cell line without the modulator, but increase
Fig. 5. CFGE analysis for Ro44-5912 effect on Dox-induced
DNA dsbs. Exponentially growing cells were pre-labeled for 20 h
with 0.025mCirml of 14C-dThyd. The 14C-labeled cells treated
for 2 h with 1.85mM Dox for A2780rwt cells and 50 mM Dox
alone, or 10 mM Dox in combination with 2 mM Ro44-5912 for
A2780rDX5 cells; washed twice and incubated in drug-free
medium with, or without Ro44-5912. Determination of DNA
dsbs was performed at 0 or 8 h after initial 2 h exposure using
CFGE. Agarose plugs, containing purified DNA, were processed
as described in Section 2. Bottom, following CFGE, each band
was cut and the quantity of 14C-labeled DNA determined. Quan-
tification of the percent of DNA released from the wells was
determined by scintillation counting.
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Fig. 6. PFGE analysis of size distributions of Dox-induced DNA
fragments. Exponentially growing cells exposed to equicytotoxic
concentrations Dox 1.85mM for A2780rwt, 50 mM or 10 mM in
.combination with 2 mM Ro44-5912 for A2780rDX5 cells for
2 h; washed twice and then incubated in drug-free medium with,
or without the modulator for 0 or 8 h. Cell harvest and prepara-
tion of DNA plugs are outlined in Fig. 5. PFGE was carried out
in two phases: phase I – 20 min pulse time, 48h running time,
and phase II – 6 min pulse time, 24h running time at 148C in
0.8% agarose. Megabase I DNA standards are suitable for sizing
linear double strand DNA from 0.1 to 1.9 Mb and Megabase IV
DNA standards are used for sizing from 1.1 to 3.3 Mb.
with time in the presence of the modulator. A signifi-
 .cant fraction of the DNA ssbs in Fig. 4 C is repaired
by 8 h. The amount of DNA ssbs in the sensitive cells
Fig. 7. Patterns of double-strand breaks in nascent DNA.
A2780rDX5 exponentially growing cells were treated for 2 h
with 10 or 50 mM Dox alone or 10 mM Dox in combination with
2 mM Ro44-5912. Cells were then labeled with 0.5mCirml of
3H-dThyd during the last two of the 24h drug-free incubation
with, or without the modulator prior to cell harvest. PFGE was
performed as described in Fig. 6. Following electrophoresis, the
 .gel was dried out and exposed to an X-ray film DuPont at
TM  .y708C with reflection intensifying screens DuPont .
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exposed to Dox with, or without Ro44-5912 did not
  .  ..change significantly Fig. 4 A vs. Fig. 4 B . The
data from Fig. 5 indicate the effect of Ro44-5912 on
Dox-induced DNA dsbs by CFGE. In the CFGE
assay system, DNA fragments below 6 Mb are eluted
from the well and tend to accumulate in a fairly
narrow compression zone close to the well. DNA
fragments larger than 6 Mb cannot enter the gel and
remain in the well. To allow comparison between
different cell lines a ratio was build as follows: DNA
released into gelrDNA released into gel q DNA
remaining in plug=100. This procedure allows
quantification of percent of DNA released from the
well and comparison of drug-induced DNA dsbs in
different cell lines even with different DNA content.
The data from Fig. 5 were comparable to that shown
in Fig. 4.
3.4. Size distribution of drug-induced DNA fragments
PFGE analysis was used to determine size distribu-
tion of Dox-induced DNA fragmentation as shown in
Fig. 6. Dox induced DNA fragments in the 50–800 kb
and 0.8–5.7 Mb ranges in A2780rwt and
A2780rDX5 cells; however, in the resistant cells
most of the Dox-induced DNA fragments were in the
0.8–5.7 Mb range. Exposure to Dox in combination
Fig. 8. Effect of Ro44-5912 on distribution of the cell cycle. Cells were exposed to equicytotoxic concentrations of Dox with, or without
the modulator Ro44-5912 for 2 h; washed twice and then incubated in drug-free medium in the presence, or absence of the modulator for
the indicated times. Following harvest, the cells were stained with propidium iodide and analyzed by flow cytometry. Red blood cells of
chicken were included to serve as an internal reference standard. Abscissa values are proportional stained DNA content and ordinate
values indicate the relative numbers of cells.
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with 2 mM Ro44-5912 potentiated DNA fragments in
the 50–800 kb range with a minor increase in 0.8–
5.7 Mb DNA fragments in the resistant cells.
3.5. Mature and newly synthesized DNA fragmenta-
tion
PFGE with radioautography provides a sensitive
assay which distinguishes dsbs in newly synthesized
and mature DNA. After drug exposure, cells were
pulse-labeled during the last 2 h prior to cell harvest
in order to determine newly synthesized DNA frag-
mentation. In the presence of 2 mM Ro44-5912, the
majority of the 3H-labeled newly synthesized DNA
fragments induced by Dox in A2780rDX5 cells were
associated with bands corresponding to the size of
 .50–800 kb Fig. 7 .
3.6. Cell-cycle perturbation
FACScan generated plots revealed that an accumu-
lation of A2780rwt and A2780rDX5 cells at the
G rM transition checkpoint was observed after drug2
treatment with Dox alone. This accumulation oc-
curred within 24 h after drug treatment for both cell
lines. However, the resistant cell line displayed a
rapid resumption of a normal cell cycle pattern,
whereas the parental cell line progressed through the
G rS boundary but remained arrested at the G rM1 2
 .phase beyond 48 h after 2 h drug exposure Fig. 8 .
When the resistant cells were exposed to 10 mM Dox
in combination with Ro44-5912 and then incubated
in a drug-free medium in the presence of the modula-
tor, the majority of cells were arrested in middle
S-phase and then progressed into late S-phase for up
to 48 h.
3.7. Blocked DNA replication
An accumulation of cells in the S-phase, which
was noted in A2780rDX5 cells exposed to 10 mM
Dox with 2 mM Ro44-5912, suggests a blockage of
cells to further DNA replication. It was shown by
flow cytometric analysis that BrdUrd incorporation
was inhibited by Dox in the presence of Ro44-5912
 .Fig. 9 . This indicates that there is indeed a block of
Fig. 9. Bivariate distribution of DNA content vs. the incorporation of BrdUrd. Cells were recovered at 0 and 24 h after 2 h exposure to
50 mM Dox or 10 mM Dox with 2 mM Ro44-5912, but incubated with BrdUrd for 20 min prior to cell harvest. They were then processed
for FACScan analysis as described in Section 2. Abscissa values are proportional stained DNA content and ordinate values indicate the
relative numbers of cells, or the incorporation of BrdUrd.
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DNA replication. An increased damage in newly
synthesized DNA may be associated with a blocked
DNA replication.
4. Discussion
In an effort to identify the mechanisms leading to
acquisition of MDR as well as to develop new treat-
ment strategies to circumvent drug resistance, we
focused on the identification of cellular determinants
involved in reversal of MDR by Ro44-5912, a newly
synthesized calcium channel blocker, in drug-re-
sistant A2780rDX5 cells. Previous investigations
have demonstrated that inhibition of drug efflux,
resulting in the restoration of cellular drug retention,
w xwas responsible for reversal of MDR 11–14,32 .
However, using equicytotoxic concentrations of Dox
with, or without Ro44-5912, significantly higher
intracellular drug concentrations were detected by
flow cytometry in A2780rDX5 cells compared to the
parental A2780 cells. The data indicate that although
restoration of intracellular drug concentration is an
essential first step in reversal of MDR, it is not
sufficient for complete restoration of drug sensitivity.
Therefore, additional cellular determinants may be
involved in the modulation of multidrug resistance.
The biological activity of most cytotoxic agents
commonly used in cancer chemotherapy has been
associated with the induction of DNA ssbs and dsbs
w x33–35 . Furthermore, the extent of DNA damage
and the rate of repair are probably important determi-
w xnants of drug sensitivity 36 . The present study
examined the effects of Ro44-5912 on the Dox-in-
duced DNA damage in drug-sensitive and resistant
cells. The results shown in Figs. 4 and 5 indicate that,
in the resistant cells, Ro44-5912 can potentiate Dox-
induced DNA ssbs and dsbs. PFGE analysis showed
that the majority of DNA fragments induced by the
combination of Dox and Ro44-5912 in the 50–800 kb
range correspond to a minor increase in the 0.8–
 .5.7 Mb DNA fragments Fig. 6 , indicating that
Ro44-5912 primarily potentiate higher molecular
weight DNA fragmentation in the 50–800 kb range.
PFGE with radioautography indicated that the major-
ity of 3H-labeled nascent DNA fragments were asso-
ciated with bands corresponding to the 50–800 kb
 .range Fig. 7 , which is similar to the average inter-
 .vals of replicons in mammalian cells 30–300 kb .
Therefore, we suggest that DNA dsbs induced by
Dox with Ro44-5912 may be correlated to replica-
tion. In addition to the restoration of intracellular
drug retention in the resistant cell line, the data imply
that the observed potentiation of replication-depen-
dent DNA damage by Dox plus Ro44-5912 might
represent an additional factor for the reversal of drug
resistance.
Replicating DNA is highly accessible to various
kinds of DNA-damaging stress resulting in the induc-
w xtion of newly synthesized DNA breaks 18–21 . DNA
replication in the nucleus of eukaryotic cells is a
complex process and restricted to the S-phase of the
w xcell cycle 22 . Initiation of DNA synthesis at repli-
con origins occurs in a defined temporal order during
w xthe S-phase 23 , permitting the interference with
replication initiation and elongation processes which
result in newly synthesized DNA breaks throughout
the S-phase. If DNA dsbs induced by Dox with
Ro44-5912 occur at replication, the process leading
to DNA damage should be active during S-phase. In
the present study an accumulation of A2780rwt and
A2780rDX5 cells at the G rM transition checkpoint2
was observed within 24 h after drug treatment with
Dox alone. However, the resistant cell line displayed
a rapid resumption of a normal cell cycle pattern,
whereas the parental cell line remained arrested at the
G rM checkpoint beyond 48 h. When the resistant2
cells were exposed to Dox in combination with
Ro44-5912, the majority of cells were arrested in
 .S-phase for up to 48 h Fig. 8 . This is consistent not
only with the recent findings that slowing transit
through the S-phase checkpoint increases the sensitiv-
w xity of cells to drug poisons 37 , but also with the
observed potentiation of replication-dependent DNA
damage by Dox plus Ro44-5912. In addition, slowing
progression through the S-phase checkpoint in the
case of A2780rDX5 cells, after exposure to Dox in
combination with Ro44-5912, may be associated with
a block to further DNA replication. The evidence that
incorporation of BrdUrd by flow cytometric analysis
was inhibited by Dox in the presence of Ro44-5912
 .implied a block of DNA replication Fig. 9 . Accord-
ingly, incorporation of 3H-dThyd into newly synthe-
sized DNA was inhibited more effectively in cells
exposed to Dox in combination with Ro44-5912 than
 .Dox alone data not shown . Thus, the S-phase delay
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is, at least in part, due to increased inhibition of DNA
synthesis.
The nature of S-phase block is not completely
understood, but may involve the activity of cyclin A
w xand Cdk 2 38–41 , which are important functional
determinants of the cell cycle regulation. Observa-
tions from our preliminary studies have indicated that
inhibition of cyclin ArCdk 2 complex formation was
observed in the cells exposed to Dox in combination
 .with Ro44-5912 data not shown . Cdk 2 bound to
cyclin A may represent an activated form of this
kinase. These results indicate that Ro44-5912 may
affect the cyclin ArCdk 2 complex which is associ-
ated with the control of cell cycle checkpoints.
Whether slowing progression through the S-phase
checkpoint and increased formation of newly synthe-
sized DNA damage is associated with altered intra-
cellular drug distribution is still not evaluated. Ling et
al. reported Dox localized predominantly in the nu-
clei of drug-sensitive cells and in the membrane of
drug-resistant cells. The rate of Dox efflux from the
nucleus was negligible in the sensitive cells but
w xmarkedly enhanced in the resistant cells 42 . How-
ever, it is not clear if specific S-phase perturbation
and increased formation of newly synthesized DNA
damage are dependent on the altered intracellular
drug distribution. Further studies are planned to in-
vestigate the correlation between alterations of cell-
cycle delays and nascent DNA fragmentation with
drug distribution in drug-sensitive and -resistant cells.
In conclusion, specific S-phase delays may corre-
late to a block in replicative DNA synthesis which
might result in the induction of newly synthesized
DNA fragmentation. The reversal of MDR by Ro44-
5912 is accompanied by specific S-phase perturbation
and the induction of nascent DNA fragmentation,
which are potentially novel cellular determinants in
addition to restoration of intracellular drug retention
for the reversal of MDR expressing P170-glyco-
protein. Cell-cycle modulation of MDR may provide
a new strategy to cancer chemotherapy.
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